ORIGINAL ARTICLE PURPOSE We aimed to compare local and metastatic recurrence of small renal masses primarily treated by cryoablation or microwave ablation.
MATERIALS AND METHODS
The MEDLINE, CINAHL, and PUBMED databases were searched to review the treatment of small renal masses with cryoablation or microwave ablation. Fifty-one studies met the inclusion criteria.
RESULTS
Fifty-one studies representing 3950 kidney lesions were analyzed. No differences were detected in the mean patient age (P = 0.150) or duration of follow-up (P = 0.070). The mean tumor size was significantly larger in the microwave ablation group compared with the cryoablation group (P = 0.030). There was no difference between microwave ablation and cryoablation groups in terms of primary effectiveness (93.75% vs. 91.27%, respectively; P = 0.400), cancer-specific survival (98.27% vs. 96.8%, respectively; P = 0.470), local tumor progression (4.07% vs. 2.53%, respectively; P = 0.460), or progression to metastatic disease (0.8% vs. 0%, respectively; P = 0.120). Patient age was predictive of overall complications in the multivariate analysis (P = 0.020). Local tumor progression with cryoablation was predicted by the mean follow-up duration using univariate (P = 0.009) and multivariate regression (P = 0.003). Clear cell and angiomyolipoma were more frequent in the microwave ablation group (P < 0.0001 and P = 0.03328, respectively), and papillary, chromophobe, and oncocytoma were more frequent in the cryoablation group (P < 0.0001, P < 0.0001, and P = 0.0004, respectively). Open access was used more often in the microwave ablation group than in the cryoablation group (12.20% vs. 1.04%, respectively; P < 0.0001), and percutaneous access was used more frequently in the cryoablation group than in the microwave ablation group (88.64% vs. 37.20%, respectively; P = 0.0021).
CONCLUSION
There is no difference in local or metastatic recurrence between cryoablation-and microwave ablation-treated small renal masses.
O
ver the past few decades, increased use of diagnostic imaging has led to a higher incidence of small renal masses through incidental discovery. From 1982 to 1997, the proportion of incidentally discovered renal tumors increased from 13% to 60%. Almost half of people with incidentally found renal masses were older than 65 years (1). As the incidence of renal cancers increases in our aging population, treatments with decreased morbidity are needed to address these smaller masses. The greater risk of end-stage renal disease after radical nephrectomy than with partial nephrectomy has encouraged the growth of elective nephron-sparing surgery (2) . Excellent disease-specific survival rates have established partial nephrectomy as the reference standard of nephron-sparing surgery (3, 4) . Laparoscopic partial nephrectomy results in less postoperative pain and more rapid recovery but is associated with a higher complication rate than open partial nephrectomy (5) .
In the past few years, ablative therapies such as cryoablation (CA), microwave ablation (MA), and radiofrequency ablation (RFA) have become increasingly available and may provide a suitable alternative to partial nephrectomy in patients who are not suitable candidates for partial nephrectomy. The established ablative method for renal cell carcinomas (RCCs) is RFA, which shows comparable oncologic outcomes to partial nephrectomy with more preservation of nephron function (6) (7) (8) . CA seems to offer the advantages of minimally invasive surgery with a significantly lower late complication rate than laparoscopic partial nephrectomy (2.2% vs. 16.3%, respectively) (9) . A recent meta-analysis showed no difference in clinical efficacy or complication rates between RFA and CA, but there remains a lack of randomized clinical trial data comparing these two ablative methods (10) . MA is now emerging in the literature; however, with the introduction of this novel technique, few studies have documented its efficacy and long-term outcomes.
RFA utilizes the flow of alternating electrical currents to induce thermal injury to a lesion (11) . To accomplish this, a closed-loop circuit containing an electrical generator, a needle electrode, grounding pads, and a patient are required to complete the circuit. The patient acts as a resistor, and the grounding pads act as large dispersive electrodes. Advantages of RFA include its minimally invasive nature, a decrease in pain for the patient, and a shorter hospital stay. Peripheral, exophytic, and small (<3 cm) tumors are associated with improved efficacy. Disadvantages include the lack of long-term clinical data, the heat sink effect (blood flow from adjacent vessels causing heat loss), and charring, which leads to decreased ablation zones (11) .
CA is used to decrease tissue temperatures to between -20°C and -50°C (12) . This causes ice formation within the extracellular space that cre-ates an osmotic gradient and vascular stasis, leading to cellular dehydration, cell membrane rupture, and local tissue ischemia. Peripherally and posteriorly located tumors improve efficacy, and central tumors may be ablated as well. Advantages include the ability to ablate tumors of any shape and the ability to control iceball margins during treatment, allowing better tumor coverage and limiting unintended injury to organs (12) .
MA works by using a microwave generator to emit an electromagnetic wave (13) . Electromagnetic microwaves agitate water molecules in the surrounding tissue, causing friction and heat and inducing cellular death via coagulation necrosis. Advantages include higher temperatures, larger tumor ablation volumes, shorter ablation times, and an improved convection profile (13) .
The reasoning for choosing to compare CA and MA is multifold. Firstly, in a period of declining research funding and limited resources for clinical research, establishing whether MA has comparable outcomes to CA could help guide future clinical research and product development. Much about MA remains unknown, particularly in comparison to other ablative methods. To the authors' knowledge, no comparison of CA and MA exists in the scientific literature, whereas CA has been previously compared to RFA. Additionally, the nature of the statistical analysis for more than two populations is complex and beyond the scope of a meta-analysis, in which two techniques are traditionally compared. Therefore, the authors restricted the comparison to CA vs. MA and excluded RFA.
The purpose of the present study was to understand how CA and MA are being used currently, the efficacy of each procedure, and relevant predictors of local and metastatic recurrence.
Materials and methods

Data collection
The MEDLINE, CINAHL, and PUBMED databases were searched in October 2012 to review reports of the treatment of small renal masses using CA or MA. Search terms included "CA", "MA", "small renal masses", and "renal cell carcinoma", as well as all possible permutations of these terms. Small renal masses were defined as solid renal tumors that enhance on computed tomography and magnetic resonance imaging and are suspected of being RCCs. Inclusion criteria were prospective and retrospective studies in which the patient population contained sporadic primary renal tumors managed by open, laparoscopic, or percutaneous CA or MA. Studies that contained patients with Von Hippel-Lindau syndrome or other hereditary cancer syndromes were excluded. In studies with overlapping patient populations, the most recent series or the series with the largest population was selected to avoid double counting of patients. In total, 51 studies met the inclusion criteria and were analyzed as shown in Table 1 .
Statistical analysis
The retrieved articles were separated into three groups: CA, MA, and the combination of both modalities. Studies that did not differentiate their findings according to ablation type ("combination group") were excluded from the analysis. Data were collected and compiled by one coder but were also reviewed by the primary author to check for consistency and completion. Results were cross-referenced with review articles to check for accuracy and comprehensiveness. Statistical analysis was performed using Statistical Package for Social Sciences (IBM SPSS Statistics version 20.0, IBM Corp., Armonk, New York, USA). Primary effectiveness was defined as the proportion of tumors without residual enhancement after one treatment session. Cancer-specific survival is the probability of surviving cancer in the absence of other causes of death. Local tumor progression is defined as any detectable local disease at follow up, either alone or in conjunction with generalized recurrence. Progression to metastatic disease is defined as the occurrence of cancer in a nonrenal location within the duration of follow-up. Baseline patient, tumor, and outcome variables were compared using a two-sided t test, with a 95% threshold for significance (P < 0.05). Univariate regression was performed using a straight line regression equation (Y=a+bX), with local recurrence and metastatic recurrence used as the dependent Y variable, and sample size, mean patient age, mean tumor size, mean duration of follow-up, and mean duration of ablation were used as independent X variables. A 95% threshold for significance (P < 0.05) was utilized. Multivariate regression was performed using local recurrence: metastatic recurrence was used as the dependent Y variable, and sample size, mean patient age, mean tumor size, mean duration of follow up, and mean duration of ablation were used as independent X variables. All variables were entered in the model in a single step, and univariate, multivariate and combined models were calculated with P values. A 95% threshold for significance (P < 0.05) was utilized. The proportion of complications that were described, proportion of lesions biopsied, and biopsy pathology results between the CA and MA groups were compared using chi-square test for the comparison of two proportions with a 95% threshold for significance (P < 0.05).
Results
Fifty-one studies, comprising 3950 kidney lesions, were analyzed ( Table  2) . No significant differences in mean patient age (P = 0.150) were found. The mean tumor size was significantly larger in the MA group than in the CA group (2.58 vs. 3.13 cm, respectively; P = 0.040). The mean duration of follow-up trended toward being shorter for MA than for CA, but the difference was not statistically significant (30.22 vs. 17 .86 months, respectively; P = 0.070). There was no difference in primary effectiveness (93.75% vs. 91.27%, P = 0.400), cancer-specific survival (98.27% vs. 96.8%, P = 0.470), local tumor progression (4.07% vs. 2.53%, P = 0.460), or progression to metastatic disease (0.8% vs. 0%, P = 0.120).
Univariate and multivariate regression analyses were performed to determine whether a series of variables are predictive of local tumor progression or metastatic progression as shown in Table 3 . The duration of follow-up was significantly predictive of metastatic progression in the univariate model (P = 0.003), and of local tumor progression in the univariate model (P = 0.009). Sample size, mean patient age, mean tumor size, and duration of ablation were not statistically significant in the univariate or multivariate analysis. Sample size, mean tumor size, mean duration of follow-up, and mean duration of ablation were not statistically significant in predicting overall, major, or minor complications in the univariate and multivariate analyses (Table 4) . Patient age was predictive of overall complications in the multivariate analysis (P = 0.020). Univariate and multivariate analyses were attempted for the MA data, but the sample size Tables 5 and 6 . The MA group had significantly more reported complications than the CA group (61.11% vs. 28%, respectively; P = 0.007). The most common complications in the MA group were fever and flank pain; in the CA group, fever and transfusion were the most common complications. Within the CA group, 35.73% were biopsied and proven to be RCCs, compared with 86.50% in the MA group (P < 0.0001). Clear cell and angiomyolipoma pathologies were documented more frequently in the MA group (P < 0.0001 and P = 0.033, respectively), and papillary, chromophobe, and oncocytoma pathologies were documented more frequently in the CA group (P < 0.0001, P < 0.0001, and P = 0.0004, respectively). The relative proportions of documented pathologies are shown in Table 7 .
CA was usually performed at a similar frequency in laparoscopic (49.17%) and percutaneous approaches (49.79%) ( Table 8 ). Open access was used more often with MA than with CA (12.20% vs. 1.04%, respectively; P < 0.0001), and percutaneous access was used more frequently with CA than with MA (88.64% vs. 37.20%, respectively; P = 0.002). These statistics were available for 3356 (88.6%) of the CA lesions and 164 (100%) of the MA lesions.
Discussion
As clinical outcomes data of small renal mass esablation using microwave and cryoablative methods begin to accumulate, the question as to which is preferable arises. The purpose of the current study was to compare differences in outcome between the aforementioned techniques. With a lack of literature directly comparing the efficacy of CA versus MA, we had to indirectly compare the two in many retrospective and prospective studies. There was no significant difference between primary effectiveness and cancer-specific survival between the CA and MA groups. Additionally, no difference was found in local tumor progression or metastatic progression.
The results of the univariate and multivariate linear regressions were largely nonsignificant. The duration of follow-up was a predictor of local and metastatic tumor progression in patients undergoing CA. This is expected because tumor recurrence generally increases with time. Patient age was also a predictor of the overall complication rate in the multivariate analysis. The same analysis was attempted for the MA data, but the sample size was too small for the analysis to be completed. However, MA had a higher fraction of reported complications than CA. The cause may be the severity of complications, the lack of standardized criteria for reporting complications, or the a Fraction reported reflects the proportion of complications described in detail, within the raw number of reported complications.
experimental nature of MA. Publication of more data regarding the use of MA for small renal masses will enable identification of predictors of primary effectiveness, cancer-specific survival, and local and metastatic tumor progression. The Society of Interventional Radiology (SIR) clinical practice guidelines provide a classification scheme for complications (65) ; however, much of the literature does not follow this classification. In addition, many of the complications may fit into multiple categories, depending on the severity of the complication and the clinical picture. Very few reports state how specific complications were classified, but instead describe the rates of complications within major or minor categories. Because the guidelines offer broad categories of complications, there may be significant interobserver differences for determining where a particular complication fits, particularly with complications that have much variability in severity, such as pain. Therefore, we could not organize complications according to SIR guidelines but instead relied on the classification used for a particular study.
With the advent of molecular classification of renal tumors, new inroads have been made in understanding how histological and molecular subtypes of RCCs affect prognosis (66, 67) . Clear-cell histology appears to be independently associated with worse outcomes in patients who undergo surgery for RCC, even after controlling for factors known to influence prognosis (66) . However, this has yet to be established for percutaneous ablative techniques. In our study, most lesions treated with MA were of the clear-cell subtype (84.40%), whereas in the CA group, these comprised a much smaller proportion of lesions (34.90%). Interestingly, although the MA group had a higher proportion of a subtype that is known to negatively affect outcomes in the surgical treatment of RCCs, primary effectiveness, cancer-specific survival, and local and metastatic recurrence were not significantly different between the CA and MA groups. There may be several reasons for this. This statistic may reflect a lack of negative prognostic value for the clear-cell subtype in ablative techniques, or MA had sufficient efficacy to overcome this negative prognostic factor. A third possibility is that due to the lack of follow up in the MA group, the statistics are favorably skewed in favor of MA, as cancer-specific survival and local or metastatic recurrence may increase with time, as shown in our linear regression analysis-albeit this relationship applied to CA and may not necessarily carry over to MA. To discriminate among these possibilities, further studies should focus on whether RCC subtype affects prognosis and the relationship of follow-up duration (and other variables) in predicting outcome in MA.
Finally, our data showed that, in the CA group, laparoscopic access was used with similar frequency to percutaneous access (49.17% vs. 49.79%, respectively), whereas laparoscopic access was favored over percutaneous access in the MA group (50.61% vs. 37.20%, respectively). Recent studies have shown that percutaneous access for CA has the benefit of shorter durations of hospital stay with no significant difference in residual and recurrent disease, overall survival, cancer-specific survival, and It is important to note that these results are not conclusive and must be interpreted with caution. Although primary effectiveness and cancer-specific survival were not significantly different, several factors may have influenced the results. The CA group had a smaller average tumor size, which may have increased both the primary effectiveness and cancer-specific survival. Conversely, follow-up duration was longer in the CA group, with a trend toward statistical significance, and may have influenced the rate of local and metastatic tumor progression, as well as primary effectiveness and cancer-specific survival. Without a direct comparison of the two techniques in a randomized trial and without baseline differences between groups, it is difficult to identify the factors that directly influenced the apparent efficacy of the two techniques. Another limitation of the current study was the statistical power. The literature involving MA for small renal masses was limited, and as such, the sample size may have been insufficient to evaluate small differences between the groups. This is evident in the metastatic tumor progression; the CA group had 0.80% of lesions progressing, while the MA group had no lesions progressing. Although the result was statistically nonsignificant, use of a larger population might have allowed evaluation of the difference in metastatic progression due to a larger sample size, resulting in an increased statistical power and a lower probability of type II error-failure to reject a false null hypothesis.
In conclusion, ablation of small renal masses is a viable strategy in patients who are not surgical candidates, have renal insufficiency, or have a solitary kidney. Current data suggest no difference in local tumor control or metastatic spread with MA, even with significantly larger tumors in the MA group and a higher proportion of clear cell and angiomyolipoma subtypes relative to the CA group. This suggests equivalent clinical efficacy in a population with a larger average tumor size and may represent a more appropriate method of treating larger tumors, which have a less favorable outcome with CA and RFA. MA avoids the charring-related impedance observed in RFA and has similar clinical and oncologic outcomes to CA. Additionally, the spectrum of complications are less severe in MA. As more reports on MA are published, further studies should compare the efficacy and cost-effectiveness of ablative therapies and evaluate factors associated with negative clinical outcomes.
